AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.

Allay Therapeutics develops targeted analgesic formulations specifically designed for post-surgical pain management, utilizing a proprietary delivery system to enhance absorption and efficacy. Their products aim to reduce opioid reliance and improve patient recovery outcomes following surgical procedures.

AstronauTx is developing targeted therapeutics to restore the functionality of astrocytes, which are critical for maintaining brain health. This approach aims to correct disrupted brain physiology associated with neurodegenerative diseases, potentially improving patient outcomes.

An AI-powered dating app that acts as a virtual wingwoman, using natural language processing and machine learning to facilitate personalized matchmaking and conversation starters. It addresses the challenges of initiating and maintaining connections in online dating by providing users with tailored suggestions and support, improving engagement and compatibility.

Axelia Oncology develops AXA-042, a systemically-delivered TLR2/6 agonist that activates the innate immune system to generate anti-tumor responses in checkpoint-insensitive cancers. This approach targets a significant unmet need in oncology by reawakening immune mechanisms to overcome resistance to existing therapies and promote long-lasting responses in solid tumors.

Azura Ophthalmics develops first-in-class ophthalmic keratolytics to treat meibomian gland dysfunction (MGD) and other ocular surface diseases. By utilizing the unique properties of keratolytics, the company targets the root causes of these conditions, addressing significant unmet patient needs in ocular health.

CatalYm is developing a monoclonal antibody, visugromab, that neutralizes GDF-15 to reverse immune resistance mechanisms in solid tumors, thereby enhancing anti-tumor immune responses. This approach aims to improve treatment outcomes for cancer patients who are non-responsive to existing therapies, addressing a significant gap in current immunotherapy effectiveness.

Certa Therapeutics is developing targeted GPR68 inhibitors to treat fibrotic diseases such as scleroderma and chronic kidney disease. Their therapies aim to reduce fibrosis progression, addressing the significant health risks associated with these life-threatening conditions.

CyclerATX is developing targeted protein degradation technology specifically for extracellular drivers of neuropsychiatric and neurodegenerative diseases. This approach aims to create effective protein degraders that can significantly enhance treatment outcomes for patients suffering from these conditions.

Denteric is developing precision immunotherapies targeting chronic infections caused by _Porphyromonas gingivalis_ (Pg), with an initial focus on severe periodontal disease. Their first product neutralizes circulating virulence factors produced by Pg, addressing the health complications associated with these infections.

Ena Respiratory is developing INNA-051, a first-in-class TLR2/6 agonist designed for self-administration via nasal delivery to enhance the innate immune response against respiratory viral infections. This product aims to reduce complications in at-risk populations by accelerating viral clearance and minimizing virus spread to the lower airways.

Entact Bio is developing enhancement-targeting chimeras (ENTACs) that utilize deubiquitylases to improve the function of critical proteins, addressing issues of protein deficiency, mislocation, and suboptimal activity in various diseases. Their Encompass™ platform enables the identification and optimization of these ENTACs to target previously undruggable pathways and treat complex genetic disorders.

Fibr AI provides an AI-powered Conversion Rate Optimization (CRO) workforce to automate website testing and personalization efforts for marketers. Its agents run high-volume experiments and dynamically adapt web content to improve post-click conversions and user engagement. This platform enables teams to scale optimization activities, reduce customer acquisition costs, and maximize marketing ROI without additional hiring.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

Medici is a mobile healthcare platform that facilitates real-time text, video, and voice communication between patients and a network of top-tier doctors, providing personalized care tailored to individual health needs. By offering 24/7 access to primary care, specialists, and emergency services without copays, Medici addresses the challenges of long wait times and fragmented healthcare access for employees and their families.

MycRx is developing oral small molecule inhibitors that specifically target the Myc oncoprotein, a critical driver of cancer progression found in over 1 million new patients annually. The company's proprietary structural biology approach has identified a unique, druggable site on Myc, positioning its compounds for effective transcriptional inhibition and significant anti-cancer activity.

Lo provides a platform for managing and automating commercial real estate leasing workflows. It centralizes lease documentation, tracks key dates, and streamlines communication between landlords and tenants. This system helps commercial property managers reduce administrative overhead and ensure compliance across their portfolio.

Myricx Bio develops novel payloads for antibody-drug conjugates (ADCs) that inhibit N-myristoyltransferases (NMT) to target cancer cells. Their proprietary ADCs demonstrate significant preclinical efficacy and safety against various solid tumor-associated antigens, addressing the need for effective cancer treatments.

NRG Therapeutics is a drug discovery company developing oral small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function. The company aims to slow or halt the progression of neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

O is developing an IoT device that visualizes the human circadian clock to enhance individual and organizational performance through data-driven insights. The platform provides actionable recommendations based on sleep data, addressing productivity issues and mental health risks within teams.

Okogen is developing a novel ophthalmic anti-infective treatment for acute infectious conjunctivitis, targeting both bacterial and adenoviral infections through a single therapeutic approach. This addresses the lack of approved treatments for adenoviral conjunctivitis, which constitutes over 90% of viral ocular infections and represents a significant gap in the current $4.2 billion conjunctivitis market.

OncoRes Medical is developing an intraoperative imaging technology that combines optical coherence tomography (OCT) and elastography to provide real-time assessment of tissue microstructure during surgery. This technology enables surgeons to evaluate tissue characteristics with a resolution comparable to histology, improving decision-making and patient outcomes.

Pathios Therapeutics is developing PTT-4256, a selective GPR65 inhibitor that targets the acidic tumor microenvironment to reverse immune cell dysfunction in solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by restoring the anti-tumorigenic activity of immune cells affected by low pH conditions.

Perx Technologies offers a self-service loyalty management platform that utilizes gamification and behavioral intelligence to enhance customer engagement. The platform enables businesses to drive user acquisition, reactivation, and retention through personalized, incentive-based campaigns that increase customer interactions and loyalty transactions.